A5029630805- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
State Healthcare Institution "Regional Clinical Oncological Dispensary"
2021
The review summarizes results of pre-clinical and clinical investigations combination therapies with interleukin-2 immune checkpoint inhibitors. It presents data the current registered trials combinations either or cytokine-activated lymphocytes. up-to-date experimental preliminary evidence that such an therapy strategy is highly promising for cancer treatment.
Immune checkpoint inhibitors (ICT) therapy is a successful immunotherapy (IT) strategy that quite effective in number of patients with non-small cell lung cancer, melanoma, bladder breast cancer and others. Nevertheless, there need predictive markers for ICT personalized IT as far large group patients, the proportion which varies depending on tumor, who do not have clinical response to such therapy. The review summarizes theoretical aspects results trials dedicated various efficiency...